156 related articles for article (PubMed ID: 27141880)
1. Design, Synthesis and Evaluation of 5-pyridin-4-yl-2-thioxo-[1,3,4]oxadiazol-3-yl Derivatives as Anti-angiogenic Agents Targeting VEGFR-2.
Bhanushali U; Kalekar-Joshi S; Kulkarni-Munshi R; Yellanki S; Medishetty R; Kulkarni P; Chelakara RS
Anticancer Agents Med Chem; 2017; 17(1):67-74. PubMed ID: 27141880
[TBL] [Abstract][Full Text] [Related]
2. 5-Benzylidene-2,4-thiazolidenedione derivatives: Design, synthesis and evaluation as inhibitors of angiogenesis targeting VEGR-2.
Bhanushali U; Rajendran S; Sarma K; Kulkarni P; Chatti K; Chatterjee S; Ramaa CS
Bioorg Chem; 2016 Aug; 67():139-47. PubMed ID: 27388635
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 6-Arylurea-2-arylbenzoxazole and 6-Arylurea-2-arylbenzimidazole Derivatives as Angiogenesis Inhibitors: Design, Synthesis and in vitro Biological Evaluation.
Zi M; Liu F; Wu D; Li K; Zhang D; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y
ChemMedChem; 2019 Jul; 14(13):1291-1302. PubMed ID: 31131561
[TBL] [Abstract][Full Text] [Related]
4. Novel VEGFR-2 inhibitors with an N-acylhydrazone scaffold.
Pauli FP; Martins JR; Paschoalin T; Ionta M; Barbosa MLC; Barreiro EJ
Arch Pharm (Weinheim); 2020 Nov; 353(11):e2000130. PubMed ID: 32667721
[TBL] [Abstract][Full Text] [Related]
5. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
[TBL] [Abstract][Full Text] [Related]
6. Quinoxalinone (Part II). Discovery of (Z)-3-(2-(pyridin-4-yl)vinyl)quinoxalinone derivates as potent VEGFR-2 kinase inhibitors.
Shi L; Zhou J; Wu J; Cao J; Shen Y; Zhou H; Li X
Bioorg Med Chem; 2016 Apr; 24(8):1840-52. PubMed ID: 26968648
[TBL] [Abstract][Full Text] [Related]
7. Design and Synthesis of Novel Thiazolo[5,4-d]pyrimidine Derivatives as Potential Angiogenesis Inhibitors.
Xue WJ; Du JY; Deng YH; Yan ZH; Liu JP; Liu Y; Sun LP
Chem Biodivers; 2019 Aug; 16(8):e1900232. PubMed ID: 31287621
[TBL] [Abstract][Full Text] [Related]
8. 12-Deoxyphorbol 13-palmitate inhibit VEGF-induced angiogenesis via suppression of VEGFR-2-signaling pathway.
Xu HY; Pan YM; Chen ZW; Lin Y; Wang LH; Chen YH; Jie TT; Lu YY; Liu JC
J Ethnopharmacol; 2013 Apr; 146(3):724-33. PubMed ID: 23434607
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, Characterization of 4-Anilino-6,7-Dimethoxy Quinazoline Derivatives as Potential Anti-Angiogenic Agents.
Devegowda PS; Balaji KS; Prasanna DS; Swaroop TR; Kameshwar VH; Jayarama S; Siddalingaiah L; Rangappa KS
Anticancer Agents Med Chem; 2018 Feb; 17(14):1931-1941. PubMed ID: 28403784
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic effect of tanshinone IIA involves inhibition of the VEGF/VEGFR2 pathway in vascular endothelial cells.
Xing Y; Tu J; Zheng L; Guo L; Xi T
Oncol Rep; 2015 Jan; 33(1):163-70. PubMed ID: 25376085
[TBL] [Abstract][Full Text] [Related]
11. Discovery of new 4-alkoxyquinazoline-based derivatives as potent VEGFR2 inhibitors.
Yin Y; Sha S; Wang YT; Wu X; Wang SF; Qiao F; Lv PC; Zhu HL
Chem Biol Drug Des; 2015 Nov; 86(5):1323-9. PubMed ID: 26032487
[TBL] [Abstract][Full Text] [Related]
12. Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase.
Rizvi SU; Siddiqui HL; Nisar M; Khan N; Khan I
Bioorg Med Chem Lett; 2012 Jan; 22(2):942-4. PubMed ID: 22200597
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents.
Aziz MA; Serya RA; Lasheen DS; Abdel-Aziz AK; Esmat A; Mansour AM; Singab AN; Abouzid KA
Sci Rep; 2016 Apr; 6():24460. PubMed ID: 27080011
[TBL] [Abstract][Full Text] [Related]
14. Development of a highly-potent anti-angiogenic VEGF8-109 heterodimer by directed blocking of its VEGFR-2 binding site.
Ghavamipour F; Shahangian SS; Sajedi RH; Arab SS; Mansouri K; Aghamaali MR
FEBS J; 2014 Oct; 281(19):4479-94. PubMed ID: 25132001
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, thymidine phosphorylase inhibition and molecular modeling studies of 1,3,4-oxadiazole-2-thione derivatives.
Shahzad SA; Yar M; Bajda M; Shahzadi L; Khan ZA; Naqvi SA; Mutahir S; Mahmood N; Khan KM
Bioorg Chem; 2015 Jun; 60():37-41. PubMed ID: 25920005
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors.
Machado VA; Peixoto D; Costa R; Froufe HJ; Calhelha RC; Abreu RM; Ferreira IC; Soares R; Queiroz MJ
Bioorg Med Chem; 2015 Oct; 23(19):6497-509. PubMed ID: 26344591
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and in vitro and in vivo anti-angiogenesis study of a novel vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor based on 1,2,3-triazole scaffold.
Wang DP; Liu KL; Li XY; Lu GQ; Xue WH; Qian XH; Mohamed O K; Meng FH
Eur J Med Chem; 2021 Feb; 211():113083. PubMed ID: 33340911
[TBL] [Abstract][Full Text] [Related]
18. Quinazoline clubbed 1,3,5-triazine derivatives as VEGFR2 kinase inhibitors: design, synthesis, docking, in vitro cytotoxicity and in ovo antiangiogenic activity.
Pathak P; Shukla PK; Kumar V; Kumar A; Verma A
Inflammopharmacology; 2018 Dec; 26(6):1441-1453. PubMed ID: 29663100
[TBL] [Abstract][Full Text] [Related]
19. Suppression of alpha-tocopherol ether-linked acetic acid in VEGF-induced angiogenesis and the possible mechanisms in human umbilical vein endothelial cells.
Chuang CH; Liu CH; Lu TJ; Hu ML
Toxicol Appl Pharmacol; 2014 Dec; 281(3):310-6. PubMed ID: 25447407
[TBL] [Abstract][Full Text] [Related]
20. The antiangiogenic activity of a soluble fragment of the VEGFR extracellular domain.
Li H; Cao W; Chen Z; Acheampong DO; Jin H; Li D; Zhang J; Wang M
Biomed Pharmacother; 2013 Sep; 67(7):599-606. PubMed ID: 23906761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
